HMGCS2在膀胱癌中的表达及其与临床病理特征的相关性分析

朱帅; 文育恒; 梁宇; 曹健; 刘侃; 叶明佶; 谢宇

doi:10.16016/j.1000-5404.202106042

您当前的位置：

首页 >

文章列表页 >

HMGCS2在膀胱癌中的表达及其与临床病理特征的相关性分析

专题报道：膀胱癌基础与临床研究 | 更新时间：2026-01-09

- HMGCS2在膀胱癌中的表达及其与临床病理特征的相关性分析
- Expression of HMGCS2 and its correlation with clinopathological characteristics in bladder cancer
- 第三军医大学学报 2021年43卷第23期页码：2552-2561
- 作者机构：
  
  410013 长沙，中南大学湘雅医学院附属肿瘤医院，湖南省肿瘤医院泌尿外科
- 作者简介：
  
  [谢宇，E-mail：xieyu420@sina.com XIE Yu, E-mail: xieyu420@sina.com
- 基金信息：
  
  国家癌症中心攀登基金临床研究项目(NCC201818A55);国家留学基金委项目(202006370028)
- DOI：10.16016/j.1000-5404.202106042
  中图分类号： R345;R730.23;R737.14
- 收稿：2021-06-06，
  
  修回：2021-09-19，
  
  纸质出版：2021-12-15
- 稿件说明：
移动端阅览
朱帅, 文育恒, 梁宇, 等. HMGCS2在膀胱癌中的表达及其与临床病理特征的相关性分析[J]. 第三军医大学学报, 2021,43(23):2552-2561.

Shuai ZHU, Yuheng WEN, Yu LIANG, et al. Expression of HMGCS2 and its correlation with clinopathological characteristics in bladder cancer[J]. Journal of Third Military Medical University, 2021, 43(23): 2552-2561.
朱帅, 文育恒, 梁宇, 等. HMGCS2在膀胱癌中的表达及其与临床病理特征的相关性分析[J]. 第三军医大学学报, 2021,43(23):2552-2561. DOI： 10.16016/j.1000-5404.202106042.

Shuai ZHU, Yuheng WEN, Yu LIANG, et al. Expression of HMGCS2 and its correlation with clinopathological characteristics in bladder cancer[J]. Journal of Third Military Medical University, 2021, 43(23): 2552-2561. DOI： 10.16016/j.1000-5404.202106042.

摘要

目的

探索3-羟甲基戊二酰辅酶A合酶2(3-hydroxy-3-methylglytaryl-CoA synthetase 2

HMGCS2)在膀胱癌中的表达水平及其与患者临床病理特征的相关性。

方法

利用GEO数据库筛选肌层浸润性膀胱癌与非肌层浸润性膀胱癌中有显著差异性表达的基因，GEPIA数据库对筛选的公共差异表达基因进行生存分析；Metascape数据库对HMGCS2及其相关基因进行功能富集分析；免疫组化染色检测临床手术切除膀胱癌样本中HMGCS2的蛋白表达情况，卡方检验分析其与患者临床病理特征的关系，Cox回归分析验证其预后效能。

结果

GEO数据库的转录组数据显示，与非肌层浸润性膀胱癌相比，HMGCS2在肌层浸润性膀胱癌中显著低表达(7.42±2.51

9.38±2.78，

0.05)；GEPIA数据库的生存分析显示，高表达HMGCS2的膀胱癌患者预后较好(总体生存期：风险比

=0.6，

=0.028；疾病无进展生存期：

=0.59，

=0.036)；KEGG、GO功能富集分析表明，HMGCS2可能参与细胞的脂肪代谢、细胞凋亡及铂类耐药，并涉及mTOR通路的信号转导；卡方检验显示HMGCS2的表达与T分期(

0.001)、组织学分级(

=0.006)、患者存活状态(

0.001)及患者疾病无进展状态(

0.001)显著相关；单因素Cox回归分析显示，HMGCS2与患者的总体生存率及疾病无进展生存率显著相关(总体生存期：

=0.104，

0.001；疾病无进展生存期：

=0.155，

0.001)；多因素Cox回归分析显示，HMGCS2是评估患者预后风险的独立预测因子(总体生存期：

=0.181，

0.001；疾病无进展生存期：

=0.312，

0.001)。

结论

HMGCS2在肌层浸润性膀胱癌中低表达，低表达的HMGCS2与患者的不良预后密切相关。

Abstract

Objective

To explore the expression of 3-hydroxymethylglutaryl-CoA synthase 2 (HMGCS2) and its correlation with the clinicopathological characteristics of patients with bladder cancer.

Methods

The GEO database was used to screen genes that were significantly differentially expressed between muscle invasive bladder cancer and non-muscle invasive bladder cancer. The survival analysis of the screened public differentially expressed genes was performed by gene expression profiling interactive analysis (GEPIA). The Metascape database was used for the functional enrichment analysis of HMGCS2 and its related genes. The expression of HMGCS2 was detected with immunohistochemical staining in clinical samples from patients with bladder cancer.

Chi

-square test was used to analyze the relationship between the expression of HMGCS2 and the clinicopathological c

haracteristics

and Cox regression analysis was adopted to verify the prognostic efficacy of HMGCS2.

Results

The transcriptome data of the GEO database showed HMGCS2 had significantly lower expression in muscle invasive bladder cancer compared with non-muscle invasive bladder cancer (7.42±2.51

9.38±2.78

0.05). The survival analysis of the GEPIA database showed that patients with high expression of HMGCS2 had better prognosis (overall survival:

=0.6

=0.028; disease progression-free survival:

=0.59

=0.036); KEGG pathway analysis and GO functional enrichment analysis showed that HMGCS2 might be involved in fat metabolism

cell apoptosis and platinum resistance

and exerted effect on the signal transduction of the mTOR pathway. In addition

the

Chi

-square test showed the expression of HMGCS2 was significantly related to the T stage (

0.001)

tissue grade (

=0.006)

patients' overall survival status (

0.001) and patients' disease-free survival status (

0.001); Univariate Cox regression analysis showed that HMGCS2 was related to the patients' overall survival rate and the disease progression-free survival rate (OS:

=0.104

0.001; DFS:

=0.155

0.001); multivariate Cox regression analysis indicated that HMGCS2 was an independent predictor of the prognostic risk of patients (OS:

=0.181

0.001; DFS:

=0.312

0.001).

Conclusion

HMGCS2 is lowly expressed in muscle invasive bladder cancer

and its low expression is closely related to the poor prognosis of patients.

关键词

Keywords

references

韩苏军, 张思维, 陈万青, 等. 中国膀胱癌发病现状及流行趋势分析[J]. 癌症进展, 2013, 11(1): 89-95. DOI: 10.3969/j.issn.1672-1535.2013.01.021.

HAN S J, ZHANG S W, CHEN W Q, et al . Analysis of the current status and epidemic trend of bladder cancer in China[J ] . Cancer Prog, 2013, 11(1): 89-95. DOI: 10.3969/j.issn.1672-1535.2013.01.021.

DEL GIUDICE F D, PECORARO M, VARGAS H A, et al . Systematic review and meta-analysis of vesical imaging-reporting and data system (VI-RADS) inter-observer reliability: an added value for muscle invasive bladder cancer detection[J ] . Cancers, 2020, 12(10): 2994. DOI: 10.3390/cancers12102994.

HURLE R, CASALE P, LAZZERI M, et al . En bloc re-resection of high-risk NMIBC after en bloc resection: results of a multicenter observational study[J ] . World J Urol, 2020, 38(3): 703-708. DOI: 10.1007/s00345-019-02805-8.

ATTA M A, KOTB A F, SHARAFELDEEN M, et al . The value of extended good quality transurethral resection of bladder tumour in the treatment of the newly diagnosed bladder cancer[J ] . Arab J Urol, 2017, 15(1): 60-63. DOI: 10.1016/j.aju.2016.10.003.

LIU W, TIAN J H, ZHANG S, et al . The utilization status of neoadjuvant chemotherapy in muscle-invasive bladder cancer: a systematic review and meta-analysis[J ] . Minerva Urol Nephrol, 2021, 73(2): 144-153. DOI: 10.23736/S0393-2249.19.03648-8.

KIM J T, LI C, WEISS H L, et al . Regulation of ketogenic enzyme HMGCS 2 by wnt/β-catenin/PPARγ pathway in intestinal cells[J ] . Cells, 2019, 8(9): E1106. DOI : 10.3390/cells8091106..

GRABACKA M, PIERZCHALSKA M, DEAN M, et al . Regulation of ketone body metabolism and the role of PPARα[J ] . Int J Mol Sci, 2016, 17(12): E2093. DOI: 10.3390/ijms17122093.

NEWMAN J C, VERDIN E. Ketone bodies as signaling metabolites[J]. Trends Endocrinol Metab, 2014, 25(1): 42-52. DOI: 10.1016/j.tem.2013.09.002.

GROMOV P, ESPINOZA J A, TALMAN M L, et al . FABP 7 and HMGCS 2 are novel protein markers for apocrine differentiation categorizing apocrine carcinoma of the breast[J ] . PLoS ONE, 2014, 9(11): e112024. DOI: 10.1371/journal.pone.0112024..

LEE Y E, HE H L, SHIUE Y L, et al . The prognostic impact of lipid biosynthesis-associated markers, HSD17B2 and HMGCS 2 , in rectal cancer treated with neoadjuvant concurrent chemoradiotherapy[J ] . Tumour Biol, 2015, 36(10): 7675-7683. DOI: 10.1007/s13277-015-3503-2..

CAMARERO N, MASCARÓ C, MAYORDOMO C, et al . Ketogenic HMGCS 2 is a c-Myc target gene expressed in differentiated cells of human colonic epithelium and down-regulated in colon cancer[J ] . Mol Cancer Res, 2006, 4(9): 645-653. DOI: 10.1158/1541-7786.mcr-05-0267..

SARAON P, CRETU D, MUSRAP N, et al . Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression[J ] . Mol Cell Proteomics, 2013, 12(6): 1589-1601. DOI: 10.1074/mcp.M112.023887.

TANG H, WU Y, QIN Y, et al . Predictive significance of HMGCS 2 for prognosis in resected Chinese esophageal squamous cell carcinoma patients[J ] . Onco Targets Ther, 2017, 10: 2553-2560. DOI: 10.2147/ott.s132543..

SU S G, YANG M, ZHANG M F, et al . miR-107-mediated decrease of HMGCS 2 indicates poor outcomes and promotes cell migration in hepatocellular carcinoma[J ] . Int J Biochem Cell Biol, 2017, 91(Pt A): 53-59. DOI: 10.1016/j.biocel.2017.08.016..

TANG Z, LI C, KANG B, et al . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J ] . Nucleic Acids Res, 2017, 45(w1): W98-W102. DOI: 10.1093/nar/gkx247.

CHANDRASHEKAR D S, BASHEL B, BALASUBRA-MANYA S A H, et al . UALCAN: a portal for facilitat ing tumor subgroup gene expression and survival analyses[J ] . Neoplasia, 2017, 19(8): 649-658. DOI: 10.1016/j.neo.2017.05.002.

ZHOU Y Y, ZHOU B, PACHE L, et al . Metascape provides a biologist-oriented resource for the analysis of systems-level datasets[J ] . Nat Commun, 2019, 10(1): 1523. DOI: 10.1038/s41467-019-09234-6.

朱帅, 许镇州, 薛蕾, 等. Adnp在膀胱尿路上皮癌组织中的表达及其临床意义[J]. 中国肿瘤生物治疗杂志, 2019, 26(11): 1214-1221. DOI: 10.3872/j.issn.1007-385x.2019.11.006.

ZHU S, XU Z Z, XUE L, et al . Expression of Adnp in bladder urothelial carcinoma and its clinical significance[J ] . Chin J Cancer Biother, 2019, 26(11): 1214-1221. DOI: 10.3872/j.issn.1007-385x.2019.11.006.

余昆, 代林, 刘胜, 等. 膀胱部分切除术与根治性全膀胱切除术治疗局限性肌层浸润性膀胱癌的临床分析[J]. 第三军医大学学报, 2018, 40(2): 169-175. DOI: 10.16016/j.1000-5404.201708212.

YU K, DAI L, LIU S, et al . Clinical analysis of partial cystectomy and radical total cystectomy in the treatment of localized myometrial invasive bladder cancer[J ] . J Third Mil Med Univ, 2018, 40(2): 169-175. DOI: 10.16016/j.1000-5404.201708212.

王猛, 滕晓东. 肌层浸润性膀胱癌的分子分型研究进展[J]. 中华病理学杂志, 2017, 46(6): 439-442. DOI: 10.3760/cma.j.issn.0529-5807.2017.06.022.

WANG M, TENG X D. Research progress in molecular classification of muscular invasive bladder cancer[J]. Chin J Pathol, 2017, 46(6): 439-442. DOI: 10.3760/cma.j.issn.0529-5807.2017.06.022.

WANG Y H, LIU C L, CHIU W C, et al . HMGCS 2 mediates ketone production and regulates the proliferation and metastasis of hepatocellular carcinoma[J ] . Cancers, 2019, 11(12): 1876. DOI: 10.3390/cancers11121876..

PAVLOVA N N, THOMPSON C B. The emerging hallmarks of cancer metabolism[J]. Cell Metab, 2016, 23(1): 27-47. DOI: 10.1016/j.cmet.2015.12.006.

GRABACKA M M, WILK A, ANTONCZYK A, et al . Fenofibrate induces ketone body production in melanoma and glioblastoma cells[J ] . Front Endocrinol (Lausanne), 2016, 7: 5. DOI: 10.3389/fendo.2016.00005.

PUCHALSKA P, CRAWFORD P A. Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics[J]. Cell Metab, 2017, 25(2): 262-284. DOI: 10.1016/j.cmet.2016.12.022.

王坤, 段鑫鑫, 姚欣. 肌层浸润性膀胱癌的精准新辅助化疗进展研究[J]. 中国肿瘤临床, 2020, 47(22): 1168-1170. DOI: 10.3969/j.issn.1000-8179.22.706.

WANG K, DUAN X X, YAO X. Advances in precision neoadjuvant chemotherapy for muscular invasive bladder cancer[J]. Chin J Clin Oncol, 2020, 47(22): 1168-1170. DOI: 10.3969/j.issn.1000-8179.22.706.

HU L T, ZHU B L, LAI Y J, et al . HMGCS 2 promotes autophagic degradation of the amyloid-β precursor protein through ketone body-mediated mechanisms[J ] . Biochem Biophys Res Commun, 2017, 486(2): 492-498. DOI: 10.1016/j.bbrc.2017.03.069..

WANG Q D, ZHOU Y N, RYCHAHOU P, et al . Ketogenesis contributes to intestinal cell differentiation[J ] . Cell Death Differ, 2017, 24(3): 458-468. DOI: 10.1038/cdd.2016.142.

PLA-MARTÍN D, SCHATTON D, WIEDERSTEIN J L, et al . CLUH granules coordinate translation of mitochondrial proteins with mTORC1 signaling and mitophagy[J ] . EMBO J, 2020, 39(9): e102731. DOI: 10.15252/embj.2019102731.

BAIZE N, MONNET I, GREILLIER L, et al . Second-line treatments of small-cell lung cancers[J ] . Expert Rev Anticancer Ther, 2017, 17(11): 1033-1043. DOI: 10.1080/14737140.2017.1372198.

KUMAR S, KUMAR A, SHAH P P, et al . MicroRNA signature of Cis-platin resistant vs . Cis-platin sensitive ovarian cancer cell lines[J ] . J Ovarian Res, 2011, 4(1): 17. DOI: 10.1186/1757-2215-4-17..

朱西, 罗生军, 蒋立, 等. Nprl2与膀胱癌患者临床病理特征的相关性及对膀胱癌细胞凋亡的影响[J]. 第三军医大学学报, 2021, 43(5): 432-437. DOI: 10.16016/j.1000-5404.202009233.

ZHU X, LUO S J, JIANG L, et al . Correlation of Nprl2 with clinicopathological characteristics of bladder cancer patients and its effect on bladder cancer cell apoptosis[J ] . J Third Mil Med Univ, 2021, 43(5): 432-437. DOI: 10.16016/j.1000-5404.202009233.

赵阳, 葛雷, 单中杰. lncRNA HULC在膀胱癌组织中的表达及其对5637细胞恶性生物学行为的影响[J]. 中国肿瘤生物治疗杂志, 2021, 28(1): 60-66. Doi: 10.3872/j.issn.1007-385x.2021.01.010.

ZHAO Y, GE L, SHAN Z J. The expression of lncRNA HULC in bladder cancer and its effect on the malignant biological behavior of 5637 cells[J]. Chin J Cancer Biother, 2021, 28(1): 60-66. DOI: 10.3872/j.issn.1007-385x.2021.01.010.

SIEWIŃSKI M, SALEH Y, POPIELA A, et al . Expression of high molecular weight cysteine proteinase inhibitor in ovarian cancer tissues: regulation of cathepsin B expression by placental CPI[J ] . Biol Chem, 2003, 384(7): 1103-1107. DOI: 10.1515/bc.2003.123.

XIONG H C, CHEN Z H, CHEN W J, et al . FKBP-related ncRNA-mRNA axis in breast cancer[J ] . Genomics, 2020, 112(6): 4595-4607. DOI: 10.1016/j.ygeno.2020.08.017.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

SNF5在膀胱癌中的表达水平及其临床意义

局部晚期或转移性肺腺癌罕见基因突变患者的临床特征和生存分析

膀胱癌循环肿瘤细胞NANOG基因的表达与临床特征相关性的初步研究

巨噬细胞分泌TNF-α调控CLDN10通路促进膀胱癌细胞上皮-间质转化

LRRC59促进膀胱尿路上皮癌细胞增殖、侵袭及凋亡抑制